Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
| ▸ | IL4 | P05112 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30608676 | 1.00 | TRPV4 (0.46) | TRPV4ADORA1ADORA2AALDH1A1DHODH | |
| SCHEMBL185766 | 0.83 | TRPV4 (0.64) | TRPV4ADORA1ADORA2AALDH1A1DHODH | |
| SCHEMBL25739687 | 0.82 | TRPV4 (0.46) | TRPV4ADORA1ADORA2AALDH1A1ADORA2B | |
| SCHEMBL29824357 | 0.80 | KHK (0.36) | TRPV4ADORA1ADORA2ADHODHADORA2B | |
| SCHEMBL14825530 | 0.78 | KHK (0.35) | TRPV4ADORA1ADORA2AALDH1A1ADORA2B | |
| SCHEMBL3298610 | 0.78 | KDM4E (0.46) | TRPV4ALDH1A1DHODHKDM4E | |
| SCHEMBL24167421 | 0.78 | TRPV4 (0.43) | TRPV4ADORA1ADORA2AIL4 | |
| SCHEMBL21563310 | 0.78 | TRPV4 (0.43) | TRPV4ADORA1ADORA2AALDH1A1DHODH | |
| SCHEMBL15674088 | 0.78 | TRPV4 (0.43) | TRPV4ADORA1ADORA2AKHKKDM4E | |
| SCHEMBL25235329 | 0.78 | TRPV4 (0.43) | TRPV4ADORA1ADORA2AALDH1A1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116940354-A | Fused heteroaryl compounds and their use as CaMKII inhibitors | 卡都瑞恩医药股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4216948-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | Cardurion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-12-29 | — | — | US | disclosed |
| US-20220098207-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2022-03-31 | — | — | US | disclosed |
| WO-2022067082-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, LLC (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20210009587-A1 | ERBB RECEPTOR INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-14 | — | — | US | disclosed |
| US-10822334-B2 | ErbB receptor inhibitors | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-5883102-A | Pharmaceutically active compounds | ASTRA PHARMACEUTICALS LIMITED (GB) | 1999-03-16 | — | — | US | disclosed |
| CN-1204327-A | Pharmaceutically active quinazoline compounds | ASTRA PHARMA PROD (GB) | 1999-01-06 | — | — | CN | disclosed |
| EP-0497213-B1 | Process for producing 3,5-difluoroaniline | ISHIHARA SANGYO KAISHA (JP) | 1995-09-27 | — | — | EP | disclosed |
| US-5399767-A | Process for producing 3,5-difluoraniline | ISHIHARA SANGYO KAISHA LTD. (JP) | 1995-03-21 | — | — | US | disclosed |
| EP-0497213-A2 | Process for producing 3,5-difluoroaniline | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | TRPV4 788/4885ADORA1 1749/4885ADORA2A 2255/4885 |
| US-20220098207-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CAMK2B, CAMK2A, CAMK2G | TRPV4 602/4885ADORA1 2886/4885ADORA2A 2438/4885 |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | ERBB2, EGFR, ERBB3 | TRPV4 823/4885ADORA1 2310/4885ADORA2A 1476/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | TRPV4 1955/4885ADORA1 3395/4885ADORA2A 3095/4885 |
| US-20210009587-A1 | ERBB RECEPTOR INHIBITORS | ERBB2, EGFR, ERBB3 | TRPV4 823/4885ADORA1 2310/4885ADORA2A 1476/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | TRPV4 3780/4885ADORA1 2560/4885ADORA2A 4151/4885 |
| US-10822334-B2 | ErbB receptor inhibitors | ERBB2, EGFR, ERBB3 | TRPV4 823/4885ADORA1 2310/4885ADORA2A 1476/4885 |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CAMK2B, RYR2, CAMK2A | TRPV4 424/4885ADORA1 1054/4885ADORA2A 1227/4885 |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CAMK2B, RYR2, CAMK2A | TRPV4 424/4885ADORA1 1054/4885ADORA2A 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.